FTC Approves Johnson & Johnson's $21.3B Acquisition of Synthes FeaturedWritten by Jaimie Oh | June 12, 2012
The Federal Trade Commission has approved Johnson & Johnson's $21.3 billion acquisition of Synthes but with one stipulation, according to a Washington Post report.
While Johnson & Johnson has been cleared to acquire Synthes, it must sell its wrist fractures unit, known as DVR, to Biomet. The FTC concluded, without this stipulation, Johnson & Johnson and Synthes would control 70 percent of the market for the wrist fracture treatment systems and harm competition.
© Copyright ASC COMMUNICATIONS 2011. Interested in LINKING to or REPRINTING this content? View our policies here.